Procurement Resource, a global leader in market research and procurement intelligence, proudly presents its latest Aminoglutethimide Production Cost Report. This detailed assessment is a strategic tool for pharmaceutical companies, investors, and contract manufacturers interested in evaluating the cost structure and feasibility of producing this key pharmaceutical compound.The report offers a deep dive into raw material economics, production methodology, technological requirements, and financial analytics, allowing stakeholders to plan investment strategies, optimize operations, and ensure regulatory compliance in the manufacture of Aminoglutethimide.
Aminoglutethimide: A Niche Yet Vital Pharmaceutical Intermediate
Aminoglutethimide is a synthetic derivative of the compound glutethimide, primarily used as a steroidogenesis inhibitor. It functions by inhibiting the enzyme aromatase, as well as P450 side-chain cleavage enzyme, thus impeding the biosynthesis of adrenal steroids. Historically used in the treatment of Cushing’s syndrome, metastatic breast cancer, and prostate cancer, Aminoglutethimide is now mostly utilized as a second-line therapy and research-grade active pharmaceutical ingredient (API).
Request Your Free Sample Today: https://www.procurementresource.com/production-cost-report-store/aminoglutethimide/request-sample
While its clinical use has declined due to newer agents, it retains significant relevance in specialized therapeutic regimens and research applications. Consequently, its production remains active among select pharmaceutical manufacturers and academic institutions.